Cellyan Biotechnology Co., Ltd
HKPDNASDAQHealthcare● Active
$0.47
$-0.02(-5.03%)
Market Cap$5159198
P/E Ratio—
52W High$2.58
52W Low$0.37
Cellyan Biotechnology Co., Ltd（HKPD）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · HKPD · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-03 | 2024-03 | 2023-03 |
|---|---|---|---|
| Revenue | |||
| Revenue | $20.31M | $16.69M | $12.56M |
| Cost of Revenue | $17.90M | $13.13M | $9.82M |
| Gross Profit | $2.42M | $3.56M | $2.74M |
| Gross Margin %(computed) | 11.89% | 21.32% | 21.81% |
| Operating Expenses | |||
| R&D Expenses | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $2.28M | $1.95M | $1.70M |
| Operating Income | $0.13M | $1.61M | $1.04M |
| Operating Margin %(computed) | 0.65% | 9.64% | 8.31% |
| Interest Income | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.10M | $0.08M | $0.02M |
| Income Before Tax | $0.04M | $1.53M | $1.02M |
| Income Tax Expense | $0.06M | $0.20M | $0.02M |
| Net Income | ($0.03M) | $1.33M | $1.00M |
| Net Margin %(computed) | -0.13% | 7.97% | 7.95% |
| Per Share & EBITDA | |||
| EPS (Basic) | $-0.00 | $0.18 | $0.09 |
| Wtd Avg Shares | 9.02M | 7.37M | 11.00M |
| EBITDA | $1.21M | $2.53M | $1.76M |
| EBITDA Margin %(computed) | 5.94% | 15.19% | 14.01% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · M
深入了解Cellyan Biotechnology Co., Ltd
关于Cellyan Biotechnology Co., Ltd（HKPD）损益表
Cellyan Biotechnology Co., Ltd（HKPD）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，HKPD实现营收$0.02B，毛利润$0.00B（毛利率11.89%），净利润($0.00B)（净利率-0.13%）。
常见问题
HKPD · 4 问Cellyan Biotechnology Co., Ltd（HKPD）2025财年营收为$0.02B，同比up21.7%。
HKPD revenueHKPD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08